Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization

the ERACE-PA Global Study Group

Research output: Contribution to journalArticlepeer-review

Abstract

The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints.

Original languageEnglish (US)
Article numbere01204-21
JournalAntimicrobial agents and chemotherapy
Volume65
Issue number11
DOIs
StatePublished - Nov 2021
Externally publishedYes

Keywords

  • Carbapenem resistance
  • Cefepime
  • Ceftazidime
  • Pharmacodynamics
  • Pharmacokinetics
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization'. Together they form a unique fingerprint.

Cite this